Long-term adherence to statin treatment in diabetes

Diabetic Medicine

Volumn 25, Issue 7, 2008, Pages 850-855

  Donnelly, L A ^a,b   Doney, A S F ^a   Morrist, A D ^a   Palmer, C N A ^a   Donnan, P T ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Mackenzie Building   (United Kingdom)

Author keywords

Adherence; Diabetes; Population; Statins

Indexed keywords

HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY LIVING; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SMOKING HABIT; TREATMENT DURATION; UNITED KINGDOM; DIABETIC ANGIOPATHY; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PSYCHOLOGICAL ASPECT;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONG-TERM CARE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 49649128889     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02476.x     Document Type: Article

References (29)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581.
2. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481-1492.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
5. Scandinavian Simvastatin Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Eng J Med 1996; 335: 1001-1009.
7. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998; 339: 1349-1357.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
9. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 18-19.
10. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RMC. Long term persistence with statin treatment in daily medical practice. Heart 2004; 90: 1065-1066.
11. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention Br J Clin Pharmacol 2005; 59: 564-573.
12. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-461.
13. Avorn J, Monette J, Lacour A, Bohn R, Monane M, Mogun H et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458-1462.
14. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-1131.
15. Jackevicius CA, Mandani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-467.
16. Costa J, Borges M, David C, Carnerio, AV. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. BMJ 2006; 332: 1115-1124.
17. Morris AD, Boyle DIR, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 1997; 315: 524-528.
18. Evans JMM, McDevitt DG, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance. Pharmaceut Med 1995; 9: 177-184.
19. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229-233.
20. Rudd P. Compliance with antihypertensive therapy: a shifting paradigm. Cardiol Rev 1994; 2: 230-240.
21. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997; 241: 317-325.
22. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
23. Hilleman D, Wurdeman RL, Lenz TL. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy 2001; 21: 410-415.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
25. Muller-Nordhorn J, Willich SN. Effectiveness of interventions to increase adherence to statin therapy. Disease Management & Health Outcomes 2005; 13: 73-82.
26. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 383-386.
27. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147-1152.
28. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87: 257-261.
29. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87: 819-822.